Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference28 articles.
1. Haematological Malignancy Research Network (HMRN). Incidence statistics: incidence by diagnosis. https://hmrn.org/statistics/incidence. Accessed 2 Aug 2022.
2. Dave SS, Fu K, Wright GW, Lam LT, Kluin age P, Boerma EJ, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–42.
3. Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood Adv. 2018;132(22):2401–5.
4. Davies AJ, Stanton L, Caddy J, Barrans S, Wilding S, Saunders GN, et al. Five-year survival results from the Remodl-B trial (ISRCTN 51837425) show improved outcomes in diffuse large B-cell lymphoma molecular subgroups from the addition of bortezomib to R-CHOP chemoimmunotherapy. Blood. 2022;140(Suppl. 1):1770–2.
5. Daneels W, Rosskamp M, Macq G, Saadoon EI, De Geyndt A, Offner F, et al. Real-world estimation of first-and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study. Front Oncol. 2022;28:485.